This video is for instructional purposes only. The vaccine vials shown in this video may differ in appearance from actual vials of PedvaxHIB.

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants younger than 6 weeks of age.

Select Safety Information

PedvaxHIB is contraindicated in patients with hypersensitivity to any component of the vaccine or the diluent; persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

As with any vaccine, the use of PedvaxHIB may not result in a protective antibody response in all vaccinees; PedvaxHIB may not induce protective antibody levels immediately following vaccination.

The most frequently reported (>1%) adverse reactions, without regard to causality, were fever (>101°F), irritability, sleepiness, injection-site pain/soreness, injection-site erythema (<2.5 cm diameter), injection-site swelling/induration (<2.5 cm diameter), unusual high-pitched crying, prolonged crying (>4 hours), diarrhea, vomiting, crying, pain, otitis media, rash, and upper respiratory infection.

Before administering PedvaxHIB, please read the Prescribing Information.

PedvaxHIB is a registered trademark of Merck & Co., Inc.